Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXNNASDAQ:ALZNNASDAQ:KZIANASDAQ:MBRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$8.88+4.7%$8.08$6.51▼$13.27$8.98M1.6294,318 shs1,373 shsALZNAlzamend Neuro$3.04+0.7%$4.58$2.90▼$135.54$2.42M-0.28456,469 shs168,566 shsKZIANovogen$9.15+2.7%$4.67$2.86▼$79.00$8.97M2.48382,590 shs146,153 shsMBRXMoleculin Biotech$0.27-54.2%$0.88$0.25▼$4.71$8.24M1.561.61 million shs16.49 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics0.00%+9.68%+10.29%+12.38%+9.14%ALZNAlzamend Neuro0.00%-5.33%-14.20%-66.78%-91.59%KZIANovogen0.00%-8.99%+151.69%+82.60%-26.09%MBRXMoleculin Biotech0.00%-13.24%-40.81%-46.79%-85.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXNAddex Therapeutics2.3202 of 5 stars3.55.00.00.00.00.80.6ALZNAlzamend Neuro2.3747 of 5 stars3.52.00.00.01.14.20.0KZIANovogen3.5843 of 5 stars3.55.00.00.02.50.00.0MBRXMoleculin Biotech3.118 of 5 stars3.55.00.00.02.50.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 3.00Buy$30.00237.88% UpsideALZNAlzamend Neuro 3.00Buy$180.005,821.05% UpsideKZIANovogen 3.00Buy$57.50528.42% UpsideMBRXMoleculin Biotech 3.00Buy$4.001,398.13% UpsideCurrent Analyst Ratings BreakdownLatest ALZN, ADXN, MBRX, and KZIA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/11/2025KZIANovogenMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.006/9/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$4.003/25/2025MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$4.003/24/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$460K20.46N/AN/A$10.37 per share0.86ALZNAlzamend NeuroN/AN/AN/AN/A($31.66) per shareN/AKZIANovogen$1.51M6.12N/AN/A($9.87) per share-0.93MBRXMoleculin BiotechN/AN/AN/AN/A$1.77 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics$8.02M-$0.34N/A∞N/A1,717.88%-61.65%-49.42%9/1/2025 (Estimated)ALZNAlzamend Neuro-$9.95MN/A0.00N/AN/AN/A-497.73%-147.21%7/29/2025 (Estimated)KZIANovogen-$17.56MN/A0.00∞N/AN/AN/AN/AN/AMBRXMoleculin Biotech-$21.76MN/A0.00N/AN/AN/A-278.80%-100.11%8/4/2025 (Estimated)Latest ALZN, ADXN, MBRX, and KZIA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MBRXMoleculin Biotech-$0.71-$0.69+$0.02-$0.69N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/AALZNAlzamend NeuroN/AN/AN/AN/AN/AKZIANovogenN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A4.424.42ALZNAlzamend NeuroN/A5.445.44KZIANovogenN/A0.21N/AMBRXMoleculin BiotechN/A1.351.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%ALZNAlzamend Neuro49.61%KZIANovogen30.89%MBRXMoleculin Biotech15.52%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%ALZNAlzamend Neuro30.21%KZIANovogen1.00%MBRXMoleculin Biotech1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.06 million901,000Not OptionableALZNAlzamend Neuro4800,000559,000No DataKZIANovogen121.01 million997,000OptionableMBRXMoleculin Biotech2014.13 million13.86 millionNot OptionableALZN, ADXN, MBRX, and KZIA HeadlinesRecent News About These CompaniesMoleculin Gets Positive FDA Feedback On Pediatric Study Plan For Annamycin In Children With R/R AMLJune 20 at 4:52 PM | nasdaq.comMoleculin Biotech prices $5.9M public offering; shares down about 47%June 20 at 11:51 AM | msn.comMoleculin Biotech, Inc. Announces Pricing of $5.9 Million Public Offering of Common Stock and Series E WarrantsJune 20 at 9:54 AM | quiverquant.comMoleculin Announces $5.9 Million Public OfferingJune 20 at 9:20 AM | globenewswire.comMoleculin Biotech (NASDAQ:MBRX) Receives "Buy" Rating from HC WainwrightJune 20 at 1:46 AM | americanbankingnews.comMoleculin Biotech, Inc.: Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AMLJune 18 at 5:02 PM | finanznachrichten.deMoleculin Biotech, Inc. Advances Annamycin for Pediatric Cancer Treatment as FDA Approves Inclusion of Younger Patients in Clinical StudyJune 18 at 8:28 AM | quiverquant.comMoleculin Participates in Virtual Investor “What This Means” SegmentJune 18 at 7:45 AM | globenewswire.comMoleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AMLJune 18 at 7:30 AM | globenewswire.comQ2 Earnings Estimate for MBRX Issued By HC WainwrightJune 13, 2025 | americanbankingnews.comMoleculin Biotech announces ‘What This Means’ virtual investor segmentJune 12, 2025 | finance.yahoo.comMoleculin Biotech, Inc. Reports Positive Topline Results from Phase 1B/2 Trial of Annamycin for Soft Tissue Sarcoma Lung MetastasesJune 11, 2025 | quiverquant.comMoleculin Participates in Virtual Investor “What This Means” SegmentJune 11, 2025 | globenewswire.comHC Wainwright Upgrades Moleculin Biotech (NASDAQ:MBRX) to BuyJune 11, 2025 | americanbankingnews.comResearch Analysts Offer Predictions for MBRX Q4 EarningsJune 11, 2025 | americanbankingnews.comMoleculin Biotech Hosts Key Opinion Leaders EventJune 5, 2025 | tipranks.comMoleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)June 5, 2025 | globenewswire.comMoleculin Biotech Reports Positive Annamycin Trial ResultsJune 4, 2025 | msn.comMoleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)June 4, 2025 | globenewswire.comMoleculin Biotech files to sell 10.99M shares of common stock, warrantsJune 2, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALZN, ADXN, MBRX, and KZIA Company DescriptionsAddex Therapeutics NASDAQ:ADXN$8.88 +0.40 (+4.72%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Alzamend Neuro NASDAQ:ALZN$3.04 +0.02 (+0.66%) Closing price 04:00 PM EasternExtended Trading$3.05 +0.01 (+0.33%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Novogen NASDAQ:KZIA$9.15 +0.24 (+2.69%) Closing price 04:00 PM EasternExtended Trading$9.29 +0.14 (+1.53%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Moleculin Biotech NASDAQ:MBRX$0.27 -0.32 (-54.20%) Closing price 04:00 PM EasternExtended Trading$0.26 0.00 (-1.12%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
